Nutra Pharma has announced their intention to begin the registration for their over-the-counter pain reliever in both Canada and Europe. Currently, the company is marketing a similar product, Cobroxin, within the United States. Cobroxin is used for the treatment of moderate to severe (Stage 2) chronic pain.
According to the North American Chronic Pain Association of Canada, it is estimated that 18% of Canadians suffer from severe chronic pain. Additionally, the Pain in Europe report, which is the largest European survey of chronic pain sufferers, reports that chronic pain effects one in five adults across Europe.
Dr. Paul Redi, CEO of ReceptoPharm, stated, “We have already started in-depth conversations with regulatory specialists with the intent to begin the registration of our over-the-counter pain reliever in Canada and Europe. We are confident that our pain reliever can be successfully registered in the near term based on the existing regulatory requirements in those territories.”
Rik J Deitsch, Chairman and CEO of Nutra Pharma, stated, “With populations exceeding 33 million people in Canada and over 830 million people throughout Europe, the combined size of the pain market in these countries potentially exceeds that of the United States. As we move forward with the registration process in Canada and Europe, we also plan to continue seeking qualified licensing partners to market and distribute our pain reliever worldwide.”
In August, Nutra Pharma introduced Cobroxin, the first OTC pain reliever clinically developed to treat chronic pain. This drug will be available in October in the form of an oral spray that treats lower pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel that treats joint pain associated with repetitive stress and arthritis. Nutra Pharma has also completed a licensing agreement that grants XenaCare Holdings the exclusive marketing and distribution rights to Cobroxin within the United States.